483 articles with Evotec AG
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.
Collaboration explores opportunities to set up antibiotic discovery and development platform and establish a joint pipeline of novel antibiotic assets
Evotec AG announced that its management will be presenting at and attending the following upcoming conferences:
Evotec Receives Milestone Payment For Start Of Second Phase Ii Trial In Its Multi-target Alliance With Bayer
Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough.
Evotec and helmholtz aim to jointly develop cystobactamid derivatives into a new class of broad spectrum antiobiotics targeting high-priority pathogens
Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG, and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications.
Evotec's partner, second genome, begins a phase ii clinical trial for nash with licensed molecule, sgm-1019
FIRST PROGRAMME ADVANCED INTO LEAD OPTIMISATION
$ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC
EVOTEC AND IMMUNEERING TO COLLABORATE ON ARTIFICIAL INTELLIGENCE ('AI') DRIVEN LIGAND IDENTIFICATION FOR RARE HEREDITARY METABOLIC DISEASES
COMBINATION OF CUTTING-EDGE IPSC AND AI TECHNOLOGIES CREATES OPPORTUNITY TO DISCOVER NOVEL METABOLIC LIGANDS TO ACCELERATE DRUG DISCOVERY IN RARE METABOLIC DISEASES
Evotec AG announced today that its management will be presenting and attending the following upcoming conferences:
Ferring will access Evotec’s integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates
Yesterday, Evotec AG (EVT) announced that Sanofi will be participating in an organized Public Private Partnership (PPP) that involves the initiation of brand newly formed BRIDGE, or LAB031, which was created to further the discovery of therapeutic drugs in multiple areas.
EVOTEC SIGNS AGREEMENT WITH SANOFI TO ADVANCE EARLY STAGE ACADEMIC RESEARCH INTO NOVEL THERAPEUTIC CANDIDATES
Evotec AG announced today that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.
Evotec AG today announced that CHDI Foundation, Inc. ("CHDI") has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
CENTOGENE and Evotec Sign Global Strategic Partnership on Drug Discovery Projects in Rare Genetic Diseases
Joint Drug Discovery Projects Combine CENTOGENE’s Patient Access and Biomarker Expertise with Evotec’s Leading iPSC Platform
Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform.
Months after partnering with Sanofi on infectious diseases, Germany-based Evotec has formed another significant partnership with Novo Nordisk. The two companies will combine their forces to develop treatments for diabetes, nonalcoholic steatohepatitis (NASH) and other diseases.
Stealth BioTherapeutics accelerates the development of a new pipeline candidate into Investigational New Drug enabling studies by leveraging Evotec's INDiGO platform